Marketdash
Back to Stock Market News

Wall Street Analysts Make Big Moves: GE Vernova Could Climb 26% and Other Top Forecasts

MarketDash Editorial Team
1 day ago
From energy infrastructure to bargain retail, Wall Street's top analysts are reshuffling their forecasts. GE Vernova gets a bullish boost while Paychex faces skepticism, and biotech names see significant target increases.

Wall Street analysts spent their Monday morning shuffling price targets and ratings across a diverse mix of companies, from energy infrastructure giants to discount retailers and biotech hopefuls. Here's what the smart money is thinking about ten stocks that caught analysts' attention.

Energy Infrastructure Gets Bullish

GE Vernova Inc (GEV) got a nice vote of confidence from Jefferies, which increased its price target from $815 to $830 while maintaining a Buy rating. With shares closing at $658.28 on Friday, that target implies roughly 26% upside if Jefferies' thesis plays out. Analyst Julien Dumoulin-Smith is clearly betting that the energy infrastructure and power generation business has room to run.

Payroll Processing Faces Skepticism

Not everyone's getting the bullish treatment, though. JP Morgan took a more cautious stance on Paychex Inc (PAYX), cutting its price target from $140 to $125. Analyst Tien-Tsin Huang maintained an Underweight rating on the payroll processing company. With shares closing at $112.28 on Friday, even the reduced target suggests limited upside in JP Morgan's view.

Bargain Hunting Gets an Upgrade

Ollie's Bargain Outlet Holdings Inc (OLLI) caught Loop Capital's eye in a good way. Analyst Anthony Chukumba upgraded the discount retailer from Hold to Buy and raised the price target from $130 to $135. That's a significant endorsement for a stock that closed at $107.97 on Friday, suggesting the analyst sees meaningful upside in the bargain retail space.

Biotech and Pharma See Target Boosts

The life sciences sector saw several optimistic moves. Cytokinetics, Inc (CYTK) received a price target increase from Citizens, which raised its forecast from $78 to $88 while maintaining a Market Outperform rating. Analyst Jason Butler is clearly enthusiastic about the biopharmaceutical company's prospects, even with shares closing at $62.72 on Friday.

Meanwhile, Outlook Therapeutics Inc (OTLK) saw Ascendiant Capital raise its target from $8 to $10, maintaining a Buy rating. That's a substantial vote of confidence for a stock trading at just $2.01 on Friday, though biotech investments at these levels come with considerable risk and volatility.

10X Genomics Inc (TXG) also got a modest bump from Canaccord Genuity, which raised its target from $19 to $20 while maintaining a Buy rating. Analyst Kyle Mikson sees upside from Friday's closing price of $16.05.

Financial Services and Real Estate Adjustments

Annaly Capital Management Inc (NLY) received a price target increase from Piper Sandler, which raised its forecast from $22.5 to $23.5. Analyst Crispin Love maintained an Overweight rating on the mortgage REIT, which closed at $22.70 on Friday.

In the homebuilding sector, KB Home (KBH) saw B of A Securities lower its price target from $62 to $58. Analyst Rafe Jadrosich maintained a Neutral rating on the homebuilder, which settled at $57.39 on Friday, suggesting the current price is roughly in line with the bank's expectations.

Media and Education Moves

Fox Corp (FOXA) got a bullish target increase from Guggenheim, which raised its forecast from $75 to $85 while maintaining a Buy rating. Analyst Michael Morris sees solid upside from Friday's closing price of $71.77 as the media company navigates the evolving broadcasting landscape.

On the flip side, McGraw Hill Inc (MH) saw Goldman Sachs cut its price target from $25 to $22, though analyst George Tong maintained a Buy rating. The education publisher closed at $17.12 on Friday, suggesting Goldman still sees upside despite the reduced target.

What It All Means

These analyst moves reflect the usual Monday morning recalibration as Wall Street digests recent market movements and company developments. Price target changes don't guarantee future performance, but they offer a window into how professional analysts are thinking about valuation and prospects across different sectors. From energy infrastructure to discount retail to biotech moonshots, the diversity of these calls shows there's no single theme dominating analyst thinking right now.

Back to Stock Market News

Wall Street Analysts Make Big Moves: GE Vernova Could Climb 26% and Other Top Forecasts

MarketDash Editorial Team
1 day ago
From energy infrastructure to bargain retail, Wall Street's top analysts are reshuffling their forecasts. GE Vernova gets a bullish boost while Paychex faces skepticism, and biotech names see significant target increases.

Wall Street analysts spent their Monday morning shuffling price targets and ratings across a diverse mix of companies, from energy infrastructure giants to discount retailers and biotech hopefuls. Here's what the smart money is thinking about ten stocks that caught analysts' attention.

Energy Infrastructure Gets Bullish

GE Vernova Inc (GEV) got a nice vote of confidence from Jefferies, which increased its price target from $815 to $830 while maintaining a Buy rating. With shares closing at $658.28 on Friday, that target implies roughly 26% upside if Jefferies' thesis plays out. Analyst Julien Dumoulin-Smith is clearly betting that the energy infrastructure and power generation business has room to run.

Payroll Processing Faces Skepticism

Not everyone's getting the bullish treatment, though. JP Morgan took a more cautious stance on Paychex Inc (PAYX), cutting its price target from $140 to $125. Analyst Tien-Tsin Huang maintained an Underweight rating on the payroll processing company. With shares closing at $112.28 on Friday, even the reduced target suggests limited upside in JP Morgan's view.

Bargain Hunting Gets an Upgrade

Ollie's Bargain Outlet Holdings Inc (OLLI) caught Loop Capital's eye in a good way. Analyst Anthony Chukumba upgraded the discount retailer from Hold to Buy and raised the price target from $130 to $135. That's a significant endorsement for a stock that closed at $107.97 on Friday, suggesting the analyst sees meaningful upside in the bargain retail space.

Biotech and Pharma See Target Boosts

The life sciences sector saw several optimistic moves. Cytokinetics, Inc (CYTK) received a price target increase from Citizens, which raised its forecast from $78 to $88 while maintaining a Market Outperform rating. Analyst Jason Butler is clearly enthusiastic about the biopharmaceutical company's prospects, even with shares closing at $62.72 on Friday.

Meanwhile, Outlook Therapeutics Inc (OTLK) saw Ascendiant Capital raise its target from $8 to $10, maintaining a Buy rating. That's a substantial vote of confidence for a stock trading at just $2.01 on Friday, though biotech investments at these levels come with considerable risk and volatility.

10X Genomics Inc (TXG) also got a modest bump from Canaccord Genuity, which raised its target from $19 to $20 while maintaining a Buy rating. Analyst Kyle Mikson sees upside from Friday's closing price of $16.05.

Financial Services and Real Estate Adjustments

Annaly Capital Management Inc (NLY) received a price target increase from Piper Sandler, which raised its forecast from $22.5 to $23.5. Analyst Crispin Love maintained an Overweight rating on the mortgage REIT, which closed at $22.70 on Friday.

In the homebuilding sector, KB Home (KBH) saw B of A Securities lower its price target from $62 to $58. Analyst Rafe Jadrosich maintained a Neutral rating on the homebuilder, which settled at $57.39 on Friday, suggesting the current price is roughly in line with the bank's expectations.

Media and Education Moves

Fox Corp (FOXA) got a bullish target increase from Guggenheim, which raised its forecast from $75 to $85 while maintaining a Buy rating. Analyst Michael Morris sees solid upside from Friday's closing price of $71.77 as the media company navigates the evolving broadcasting landscape.

On the flip side, McGraw Hill Inc (MH) saw Goldman Sachs cut its price target from $25 to $22, though analyst George Tong maintained a Buy rating. The education publisher closed at $17.12 on Friday, suggesting Goldman still sees upside despite the reduced target.

What It All Means

These analyst moves reflect the usual Monday morning recalibration as Wall Street digests recent market movements and company developments. Price target changes don't guarantee future performance, but they offer a window into how professional analysts are thinking about valuation and prospects across different sectors. From energy infrastructure to discount retail to biotech moonshots, the diversity of these calls shows there's no single theme dominating analyst thinking right now.